A reduced dose of ribavirin does not influence the virologic response during pegylated interferon alpha-2b and ribavirin combination therapy in patients with genotype 1 chronic hepatitis C
Background/AimsWhen combined with pegylated interferon alpha-2b (Peg-IFN α-2b) for the treatment of genotype 1 chronic hepatitis C (CHC) in Korea, the current guideline for the initial ribavirin (RBV) dose is based on body weight. However, since the mean body weight is lower for Korean patients than...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Korean Association for the Study of the Liver
2012-09-01
|
| Series: | Clinical and Molecular Hepatology |
| Subjects: | |
| Online Access: | http://e-cmh.org/upload/pdf/cmh-18-272.pdf |
| _version_ | 1830475155217842176 |
|---|---|
| author | Byung Chul You Young Seok Kim Hun il Kim Se Hun Kim Seung Sik Park Yu Ri Seo Sang Gyune Kim Se Whan Lee Hong Soo Kim Soung Won Jeong Jae Young Jang Boo Sung Kim |
| author_facet | Byung Chul You Young Seok Kim Hun il Kim Se Hun Kim Seung Sik Park Yu Ri Seo Sang Gyune Kim Se Whan Lee Hong Soo Kim Soung Won Jeong Jae Young Jang Boo Sung Kim |
| author_sort | Byung Chul You |
| collection | DOAJ |
| description | Background/AimsWhen combined with pegylated interferon alpha-2b (Peg-IFN α-2b) for the treatment of genotype 1 chronic hepatitis C (CHC) in Korea, the current guideline for the initial ribavirin (RBV) dose is based on body weight. However, since the mean body weight is lower for Korean patients than for patients in Western countries, current guidelines might result in Korean patients being overdosed with RBV.MethodsWe retrospectively reviewed the medical records of patients with genotype 1 CHC who were treated with Peg-IFN α-2b and RBV combination therapy. We divided the patients into groups A (≥15 mg/kg/day, n=23) and B (<15 mg/kg/day, n=26), given that the standard dose is 15 mg/kg/day. The clinical course in terms of the virologic response, adverse events, and dose modification rate was compared between the two groups after therapy completion.ResultsThe early response rates (92.0% vs. 83.3%, P=0.634) and sustained virologic response rates (82.6% vs. 73.1%, P=0.506) did not differ significantly between the two groups. During the treatment period, the RBV dose reduction rate was significantly higher in group A than in group B (60.9% vs. 23.1%, P=0.01).ConclusionsRBV dose reduction is performed frequently when patients are treated according to the current Korean guidelines. Given that lowering the RBV dose did not appear to decrease the virologic response during therapy, reducing RBV doses below the current Korean guideline may be effective for treatment, especially in low-weight patients. |
| first_indexed | 2024-12-21T15:31:31Z |
| format | Article |
| id | doaj.art-78e16b5c30384dd1bd7a456066f800e1 |
| institution | Directory Open Access Journal |
| issn | 2287-2728 2287-285X |
| language | English |
| last_indexed | 2024-12-21T15:31:31Z |
| publishDate | 2012-09-01 |
| publisher | Korean Association for the Study of the Liver |
| record_format | Article |
| series | Clinical and Molecular Hepatology |
| spelling | doaj.art-78e16b5c30384dd1bd7a456066f800e12022-12-21T18:58:46ZengKorean Association for the Study of the LiverClinical and Molecular Hepatology2287-27282287-285X2012-09-0118327227810.3350/cmh.2012.18.3.272991A reduced dose of ribavirin does not influence the virologic response during pegylated interferon alpha-2b and ribavirin combination therapy in patients with genotype 1 chronic hepatitis CByung Chul You0Young Seok Kim1Hun il Kim2Se Hun Kim3Seung Sik Park4Yu Ri Seo5Sang Gyune Kim6Se Whan Lee7Hong Soo Kim8Soung Won Jeong9Jae Young Jang10Boo Sung Kim11Department of Internal Medicine, Soon Chun Hyang University Bucheon Hospital, Soon Chun Hyang University College of Medicine, Bucheon, Korea.Department of Internal Medicine, Soon Chun Hyang University Bucheon Hospital, Soon Chun Hyang University College of Medicine, Bucheon, Korea.Department of Internal Medicine, Soon Chun Hyang University Bucheon Hospital, Soon Chun Hyang University College of Medicine, Bucheon, Korea.Department of Internal Medicine, Soon Chun Hyang University Bucheon Hospital, Soon Chun Hyang University College of Medicine, Bucheon, Korea.Department of Internal Medicine, Soon Chun Hyang University Bucheon Hospital, Soon Chun Hyang University College of Medicine, Bucheon, Korea.Department of Internal Medicine, Soon Chun Hyang University Bucheon Hospital, Soon Chun Hyang University College of Medicine, Bucheon, Korea.Department of Internal Medicine, Soon Chun Hyang University Bucheon Hospital, Soon Chun Hyang University College of Medicine, Bucheon, Korea.Department of Internal Medicine, Soon Chun Hyang University Cheonan Hospital, Soon Chun Hyang University College of Medicine, Cheonan, Korea.Department of Internal Medicine, Soon Chun Hyang University Cheonan Hospital, Soon Chun Hyang University College of Medicine, Cheonan, Korea.Department of Internal Medicine, Soon Chun Hyang University Seoul Hospital, Soon Chun Hyang University College of Medicine, Seoul, Korea.Department of Internal Medicine, Soon Chun Hyang University Seoul Hospital, Soon Chun Hyang University College of Medicine, Seoul, Korea.Department of Internal Medicine, Soon Chun Hyang University Bucheon Hospital, Soon Chun Hyang University College of Medicine, Bucheon, Korea.Background/AimsWhen combined with pegylated interferon alpha-2b (Peg-IFN α-2b) for the treatment of genotype 1 chronic hepatitis C (CHC) in Korea, the current guideline for the initial ribavirin (RBV) dose is based on body weight. However, since the mean body weight is lower for Korean patients than for patients in Western countries, current guidelines might result in Korean patients being overdosed with RBV.MethodsWe retrospectively reviewed the medical records of patients with genotype 1 CHC who were treated with Peg-IFN α-2b and RBV combination therapy. We divided the patients into groups A (≥15 mg/kg/day, n=23) and B (<15 mg/kg/day, n=26), given that the standard dose is 15 mg/kg/day. The clinical course in terms of the virologic response, adverse events, and dose modification rate was compared between the two groups after therapy completion.ResultsThe early response rates (92.0% vs. 83.3%, P=0.634) and sustained virologic response rates (82.6% vs. 73.1%, P=0.506) did not differ significantly between the two groups. During the treatment period, the RBV dose reduction rate was significantly higher in group A than in group B (60.9% vs. 23.1%, P=0.01).ConclusionsRBV dose reduction is performed frequently when patients are treated according to the current Korean guidelines. Given that lowering the RBV dose did not appear to decrease the virologic response during therapy, reducing RBV doses below the current Korean guideline may be effective for treatment, especially in low-weight patients.http://e-cmh.org/upload/pdf/cmh-18-272.pdfRibavirinPegylated interferon alpha-2bChronic hepatitis CSustained virologic responseKoreans |
| spellingShingle | Byung Chul You Young Seok Kim Hun il Kim Se Hun Kim Seung Sik Park Yu Ri Seo Sang Gyune Kim Se Whan Lee Hong Soo Kim Soung Won Jeong Jae Young Jang Boo Sung Kim A reduced dose of ribavirin does not influence the virologic response during pegylated interferon alpha-2b and ribavirin combination therapy in patients with genotype 1 chronic hepatitis C Clinical and Molecular Hepatology Ribavirin Pegylated interferon alpha-2b Chronic hepatitis C Sustained virologic response Koreans |
| title | A reduced dose of ribavirin does not influence the virologic response during pegylated interferon alpha-2b and ribavirin combination therapy in patients with genotype 1 chronic hepatitis C |
| title_full | A reduced dose of ribavirin does not influence the virologic response during pegylated interferon alpha-2b and ribavirin combination therapy in patients with genotype 1 chronic hepatitis C |
| title_fullStr | A reduced dose of ribavirin does not influence the virologic response during pegylated interferon alpha-2b and ribavirin combination therapy in patients with genotype 1 chronic hepatitis C |
| title_full_unstemmed | A reduced dose of ribavirin does not influence the virologic response during pegylated interferon alpha-2b and ribavirin combination therapy in patients with genotype 1 chronic hepatitis C |
| title_short | A reduced dose of ribavirin does not influence the virologic response during pegylated interferon alpha-2b and ribavirin combination therapy in patients with genotype 1 chronic hepatitis C |
| title_sort | reduced dose of ribavirin does not influence the virologic response during pegylated interferon alpha 2b and ribavirin combination therapy in patients with genotype 1 chronic hepatitis c |
| topic | Ribavirin Pegylated interferon alpha-2b Chronic hepatitis C Sustained virologic response Koreans |
| url | http://e-cmh.org/upload/pdf/cmh-18-272.pdf |
| work_keys_str_mv | AT byungchulyou areduceddoseofribavirindoesnotinfluencethevirologicresponseduringpegylatedinterferonalpha2bandribavirincombinationtherapyinpatientswithgenotype1chronichepatitisc AT youngseokkim areduceddoseofribavirindoesnotinfluencethevirologicresponseduringpegylatedinterferonalpha2bandribavirincombinationtherapyinpatientswithgenotype1chronichepatitisc AT hunilkim areduceddoseofribavirindoesnotinfluencethevirologicresponseduringpegylatedinterferonalpha2bandribavirincombinationtherapyinpatientswithgenotype1chronichepatitisc AT sehunkim areduceddoseofribavirindoesnotinfluencethevirologicresponseduringpegylatedinterferonalpha2bandribavirincombinationtherapyinpatientswithgenotype1chronichepatitisc AT seungsikpark areduceddoseofribavirindoesnotinfluencethevirologicresponseduringpegylatedinterferonalpha2bandribavirincombinationtherapyinpatientswithgenotype1chronichepatitisc AT yuriseo areduceddoseofribavirindoesnotinfluencethevirologicresponseduringpegylatedinterferonalpha2bandribavirincombinationtherapyinpatientswithgenotype1chronichepatitisc AT sanggyunekim areduceddoseofribavirindoesnotinfluencethevirologicresponseduringpegylatedinterferonalpha2bandribavirincombinationtherapyinpatientswithgenotype1chronichepatitisc AT sewhanlee areduceddoseofribavirindoesnotinfluencethevirologicresponseduringpegylatedinterferonalpha2bandribavirincombinationtherapyinpatientswithgenotype1chronichepatitisc AT hongsookim areduceddoseofribavirindoesnotinfluencethevirologicresponseduringpegylatedinterferonalpha2bandribavirincombinationtherapyinpatientswithgenotype1chronichepatitisc AT soungwonjeong areduceddoseofribavirindoesnotinfluencethevirologicresponseduringpegylatedinterferonalpha2bandribavirincombinationtherapyinpatientswithgenotype1chronichepatitisc AT jaeyoungjang areduceddoseofribavirindoesnotinfluencethevirologicresponseduringpegylatedinterferonalpha2bandribavirincombinationtherapyinpatientswithgenotype1chronichepatitisc AT boosungkim areduceddoseofribavirindoesnotinfluencethevirologicresponseduringpegylatedinterferonalpha2bandribavirincombinationtherapyinpatientswithgenotype1chronichepatitisc AT byungchulyou reduceddoseofribavirindoesnotinfluencethevirologicresponseduringpegylatedinterferonalpha2bandribavirincombinationtherapyinpatientswithgenotype1chronichepatitisc AT youngseokkim reduceddoseofribavirindoesnotinfluencethevirologicresponseduringpegylatedinterferonalpha2bandribavirincombinationtherapyinpatientswithgenotype1chronichepatitisc AT hunilkim reduceddoseofribavirindoesnotinfluencethevirologicresponseduringpegylatedinterferonalpha2bandribavirincombinationtherapyinpatientswithgenotype1chronichepatitisc AT sehunkim reduceddoseofribavirindoesnotinfluencethevirologicresponseduringpegylatedinterferonalpha2bandribavirincombinationtherapyinpatientswithgenotype1chronichepatitisc AT seungsikpark reduceddoseofribavirindoesnotinfluencethevirologicresponseduringpegylatedinterferonalpha2bandribavirincombinationtherapyinpatientswithgenotype1chronichepatitisc AT yuriseo reduceddoseofribavirindoesnotinfluencethevirologicresponseduringpegylatedinterferonalpha2bandribavirincombinationtherapyinpatientswithgenotype1chronichepatitisc AT sanggyunekim reduceddoseofribavirindoesnotinfluencethevirologicresponseduringpegylatedinterferonalpha2bandribavirincombinationtherapyinpatientswithgenotype1chronichepatitisc AT sewhanlee reduceddoseofribavirindoesnotinfluencethevirologicresponseduringpegylatedinterferonalpha2bandribavirincombinationtherapyinpatientswithgenotype1chronichepatitisc AT hongsookim reduceddoseofribavirindoesnotinfluencethevirologicresponseduringpegylatedinterferonalpha2bandribavirincombinationtherapyinpatientswithgenotype1chronichepatitisc AT soungwonjeong reduceddoseofribavirindoesnotinfluencethevirologicresponseduringpegylatedinterferonalpha2bandribavirincombinationtherapyinpatientswithgenotype1chronichepatitisc AT jaeyoungjang reduceddoseofribavirindoesnotinfluencethevirologicresponseduringpegylatedinterferonalpha2bandribavirincombinationtherapyinpatientswithgenotype1chronichepatitisc AT boosungkim reduceddoseofribavirindoesnotinfluencethevirologicresponseduringpegylatedinterferonalpha2bandribavirincombinationtherapyinpatientswithgenotype1chronichepatitisc |